TFF Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, has expanded its engagement with one of its Contract Manufacturing Organizations (CMOs), Experic LLC, with an agreement to install a Thin Film Freezing processing line and its associated capabilities at Experic’s cGMP facility in Cranbury, New Jersey.
 
Installation of TFF’s custom-designed equipment is expected to be completed in early Q2-2021. This will increase TFF’s manufacturing capacity, as well as provide a third cGMP manufacturing location for the company.
 
“This expansion of our manufacturing operations at Experic gives us the capability and capacity to develop and produce additional products currently in assessment with pharmaceutical company partners,” said Glenn Mattes, president and CEO of TFF Pharmaceuticals. “Experic has been a terrific partner for us because of their domain expertise in dry powder inhalation products. They also provide us with unique downstream encapsulation technology that rounds out the specialized manufacturing requirements of our dry powder inhalation therapies.”
 
“The entire Experic team is thrilled to be working with TFF Pharmaceuticals and supporting development and manufacturing activities using its Thin Film Freezing (TFF) technology,” added Jeffrey P. McMullen, chairman and CEO of Experic. “We share their excitement in the continued advancement and expansion of their technology and business.”